Mounjaro® providers &
prescriptions in New Smyrna Beach, FL
Verified Mounjaro providers in New Smyrna Beach, FL. Checked against the NPI registry, never ranked by who pays us.[7]
Find a Mounjaro provider in Florida.
Every entry is checked against the federal NPI registry. We do not accept payment for placement.
How to get Mounjaro in New Smyrna Beach.
25 GLP-1 prescribers and 7 local resource types are on record for New Smyrna Beach, plus 3 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.
Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]
In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]
Community health · CDC
Weight & metabolic health in New Smyrna Beach
New Smyrna Beach, Florida has a population of 30,142 people. The adult obesity rate in New Smyrna Beach is an age-adjusted estimate of 30.8%, 1.2 percentage points above the Florida state rate of 29.6%. Diagnosed diabetes reaches 8.7% of adults in New Smyrna Beach. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 20% of adults in New Smyrna Beach.
- of New Smyrna Beach adults have obesity
- 30.8%
- diagnosed diabetes
- 8.7%
- no regular physical activity
- 20%
Age-adjusted estimates for New Smyrna Beach, community figures, not individual risk. CDC PLACES, 2025 release.
The prescription is one part. Here is the rest, in New Smyrna Beach.
Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near New Smyrna Beach, FL, ordered as the registry lists them, never by who pays us.
Nutritionists
A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.
Fitness clubs and recreation centers
Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.
What the trials actually showed.
We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Mounjaro (tirzepatide) prescribers and clinics, never ranked by who pays us.
Find NPI-verified Mounjaro (tirzepatide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.
Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]